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ROLE OF THE HYBRID Bcr/Abl KINASE IN THE PATHOGENESIS 
OF CHRONIC MYELOID LEUKEMIA LACKING C-Abl 
AND CXCR4 PROTEINS
L.A. Polishchuk*, G.D. Telegeev
Institute of Molecular Biology and Genetics of NAS of Ukraine, Kyiv 03143, Ukraine
Philadelphia chromosome is a result of chromosomal rearrangement that leads to the appearing of the hybrid gene bcr/abl. A hybrid 
mRNA transcribes from bcr-promoter and many copies of hybrid molecules of Bcr/Abl protein are formed as a result of bcr/abl gene 
expression. It is supposed that a hybrid Abl molecule, replacing the normal one, in majority of cases functions abnormally or does not 
function at all. Also it is possible that Abl moiety of Bcr/Abl protein which is possibly recognized by some hypothetical cell control system 
interpreted by cell as an overproduction of c-abl. This, probably, leads to blocking the normal C-Abl molecules production from the nor-
mal c-abl gene transcribed from the second non-aberrant chromosome 9. Based on C-Abl physiological functions in conjunction with 
the most important proteins of which functions directly depend on its activity we tried to outline the research directions that might ex-
plain disruptions of the processes at chronic myeloleukosis such as cell migration due to CXCL12/CXCR4 axis activation, reparation, 
apoptosis, control for mitochondria state, and to propose new perspective therapeutic approaches based on all this knowledge.
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C-Abl PROTEIN
140 kDa C-Abl protein is expressed in cells and 
localized in cell nucleus, on plasma membrane and 
cytoskeleton [1]. There are two different forms of C-Abl 
(types 1a and 1b), that result from alternative splicing 
of two small exons. Type 1a C-Abl contains C14 myris-
toyil fatty acid covalently bound to N-terminal region, 
and its expression level is higher than in 1b type. 
N-terminal region of C-Abl kinase is similar to those 
from Src family proteins and contains SH3 homology 
domain, SH2 domain and catalytic domain, but C-Abl 
differs from Src because of a bigger (60 kDa) C-ter-
minal domain [1]. The mechanism of C-Abl catalytic 
activity regulation remains unknown [2].
PHYSIOLOGICAL ROLE OF C-Abl
C-Abl protein is widespread within cell; usually 
it is present at the tips of lamellipodia and filopodia [3, 
4–8] and is localized in nucleus, cytoplasm, mitochon-
dria and endoplasmic reticulum [9]. C-Abl is involved 
in a wide number of processes, such as regulation 
of cell growth and survival, oxidative stress reaction, 
response to DNA damage, also it plays some role in ac-
tin dynamics and cell migration [9]. While in nucleus 
C-Abl is connected to Rb protein and is not active 
during G0 and G1 phases of cell cycle. After  starting 
of S phase Rb protein becomes phosphorylated 
that results in releasing C-Abl kinase from this com-
plex [10]. In nucleus C-Abl kinase is used as apoptosis 
regulator and is also involved in the processes of repa-
ration and recombination [11, 12]. It is known that ATM 
kinase, C-Abl and Rad51 are found as a complex after 
co-immunoprecipitation from plant extracts [13, 14]. 
C-Abl kinase activates p53 protein as well [13, 14].
C-Abl also has the ability to phosphorylate 
RAD52 [15] and RAD51 [16] proteins. After C-Abl 
phoshorylates Rad51, this protein forms a complex 
with RAD52 [15]. On obtaining signal from ATM ki-
nase special protein instruments become active and 
perform reparation of DNA defects during G1 phase, 
and in case of irreparable damages induction of p53-
mediated apoptosis takes place [17]. C-Abl binds 
to p53 and thus affects its activity. Also c-Abl contri-
butes to p21 expression that confirms the participa-
tion of c-Abl in p53-dependent G1 phase control [17]. 
C-Abl also functions as proapoptotic JNK/SAPK and 
p38 MAPK pathways [17]. Moreover, ATM kinase 
also forms complex with C-Abl [13, 14]. ATM kinase 
together with NBS1 protein acts as primary detec-
tor of double-strand breaks of DNA in G1/S and 
G2/M checkpoints [18].
Cytoplasmic C-Abl also has important functions. 
It has been already mentioned that this protein is found 
in tips of lamellipodia and filopodia. C-Abl phosphory-
lates WAVE3 protein at four tyrosine residues, that pre-
sumably makes actin cytoskeleton dynamics possible, 
that is necessary for changing cell shape, adhesion 
property and migration [4–8]. Special Arg protein that 
is important in this process is also pre sent here [19]. 
Cytoplasmic forms of C-Abl and Arg are activated 
after cell response to the oxidative stress [20–22]. 
GPx1 functions as a substrate for C-Abl-Arg-mediated 
phosphorylation at Tyr-96.  C-Abl and Arg stimulate 
GPx activity and provide Gpx-mediated protection 
of cells from the oxidative stress [22]. Activation 
of C-Abl-Arg complex occurs after it contacts the mi-
tochondria lacking transmembrane potential after cy-
tochrome C release [21, 23]. H2O2-induced apoptosis 
mitigates in cells under lack of c-Abl or expression 
of kinase-inactive mutant Arg (K-R) [22]. Thus, c-Abl-
Arg heterodimers are important for control of ROS rise 
and for apoptotic answer to the oxidative stress [22, 
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24]. This supports the hypothesis that in this case hy-
perexpressed Bcr/Abl doesn’t perform the physiologi-
cal function of normal c-Abl that either doesn’t express 
or cannot compete with Bcr/Abl. So, the lack of this 
kinase activity might be the reason of the oxidative 
stress occurred. This assumption could also be ex-
tended to cell movement: Arg protein together with 
C-Abl also participates in lamellipodia and filopodia 
formation and activity [19]. In case of hyperexpression 
of Bcr/Abl some “paralysis”of lamellipodia and filo-
podia might occur. The same extrapolation to the role 
of Bcr/Abl in reparation is also possible: C-Abl exists 
normally in nucleus as a part of “reparation manipula-
tor” — RAD52 complex that provides mechanical com-
bination of broken DNA strands. In case of reparation 
inability the apoptosis is induced due to c-Abl and p53. 
If transcription of the normal c-abl gene is inhibited and 
C-Abl lack results in nucleus (because of the kinase-
inactive Bcr/Abl presence in cytoplasm) the process 
of apoptosis initiation is blocked [17, 18].
One of the important physiological processes that 
is disrupted in chronic myelogenous leukemia (CML) 
and into which C-Abl is involved it is probably the moti-
lity of lamellipodia and filopodia during cell migration. 
As it has been discovered, migration of hematopoi-
etic stem cell occurs under the constitutive CXCL12/
CXCR4 axis activity [25]. This aspect is important for 
investigation of c-Abl influence on chemotaxis.
CHEMOTAXIS AND CXCL12/CXCR4 AXIS
Chemokines are the class of small (8–10 kDa) 
inflammatory or homeostatic cytokines which main 
biological activity is to control migration of different 
cell types. This includes lymphocytes, monocytes, 
neutrophils, endothelial cell, mesenchymal stem cells, 
malignant cells of epithelial nature, as it exactly occurs 
in early ontogenesis on different stages of embryonic 
metamorphosis. The same occurs in adult organism, 
where stem cells migration during differentiation and 
immune responses is necessary [26–28]. High affi nity 
of chemokines to heparin prevents its distribution all 
over the space and forms local gradients [29, 30]. 
Chemokines consist of three conserved groups of ele-
ments: СХС, CC, C and also CX3C group depending 
on the quantity of N-terminal cysteine residues and 
gaps between them. CXC chemokines have a single 
non-conserved aminoacid residue (X) between first 
N-terminal residues (C). Chemokines CC have two ad-
jacent cysteine residues. C chemokines have only one 
N-terminal cysteine while CX3C chemokines contain 
three non-conserved aminoacid residues separated 
by N-terminal cysteine pairs. After activation GPCR 
acts as guanidine-exchanging factor (GEF), promoting 
conformational change in Gα sub-unit and substi tuting 
the bound GDP into GTP. This exchange promotes 
subsequent conformational changes in Gα subunit 
and that allows trimer G-proteins releasing from 
the receptor and forming the GTP-bound Gα subunit 
and £В/G dimer. Both active components interact with 
different effector proteins and initiate unique intra-
cellular signal cascades, for example, phosholipase 
C (PLC) activation, regulation of adenylatecyclase, 
including pathways of mitogen-activating protein ki-
nase (MAPK) activation, c-Jun kinase (JNK), p38 and 
phosphoinositol-3-kinase (PI3K) [31–34].
Chemokine CXCL12 (SDF-1) and its cell surface 
receptor CXCR4 have been first identified as regula-
tors of lymphocytes circulation in bone marrow [35]. 
Shortly after, it has been identified that CXCL12/
CXCR4 axis is a regulator of breast cancer cells migra-
tion to loci of methastasis [29]. It has been recently 
found that CXCR4 plays a central role in cancer cells 
proliferation, invasion and spread of tumor cells in ma-
jority of malignant diseases [28].
CXCL12/CXCR4 axis is widespread in vertebrates 
and in human organism. Recent works have shown that 
CXCL12 also binds to one more chemokine receptor 
as CXCR7 is [35]. It has been given much attention 
to the study of CXCR4 because it works as a means 
of viruses (X4) penetration into T cells during HIV 
infection [36, 37]. Mouse and human chemokines 
CXCL12 are cross-reactive and differ by only one 
aminoacid. CXCL12 and CXCR4 play an important 
role in human stem cells migration and colonization 
in immune-deficient mice both NOD/SCID and B2mnull-
NOD/SCID [38].
Studies of early human and other mammalian 
ontogenesis showed that CXCR4 has been identified 
more often than other chemokine receptors, especially 
in the process of gastrulation. During gastrulation 
CXCR4 expresses in tissues that later migrates through 
the primitive streak of ectoderm [26]. Primary blood 
cells in embryogenesis emerge at the early stage 
of the yolk sac. Analysis of 69 separate cell isolates has 
shown that most of them had CXCR4 receptor. Other 
strains instead had CCR4 chemokine receptor [29].
Using zebra fish model it has been shown 
that  G-protein receptor CXCR4 and a chemokine 
CXCL12 as its ligand play an important role in migration 
of gonocytes to gonads [39]. Colonization of mouse 
embryonic gonads by gonocytes also occurs to ligand-
receptor interaction between CXCL12 and CXCR4 [40]. 
Thus gonocytes express CXCR4 and cells of genital rid-
ges of gonadal primordial express CXCL12 chemokine.
CXCL12 also concentrates at peripheral neuronal 
cranial tissue in pia mater. Expression of CXCL12 in pia 
mater occurs in close proximity of CXCR4-expressing 
neurons. Among many factors of CXCL12-CXCR4 axis 
action it is interesting that CXCR4 expresses at high 
levels in immune system cells — monocytes, lym-
phocytes, T-cells, and also in early hematopoietic 
progenitor cells in bone marrow [41].
Thus, CXCL12-CXCR4 axis in organisms of verte-
brates is the main universal instrument of organization 
of directed stem cells migration to the places of their 
permanent living at all stages of ontogenesis.
It is known that hematopoietic stem cells have high 
hierarchy of differentiation [42]. Early cells-progenitors 
produce cell next generations with more advanced dif-
ferentiation stage. They in turn produce cells of later 
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cytotype, and so on. It has been revealed that there 
are not only several consistent types of stem cells, but 
also special niches for their growth exist that are lo-
cated at different places. For subsequent proliferation 
each stem cell has to migrate to a new region where 
chemokine secretion occurs [38].
ROLE OF CHEMOTAXIS IN CML
When gradient of chemokine which is available for 
cell receptors forms around the place of hematopoietic 
stem cells localization, cell polarizes [43]. A special 
“leg” with integrins for interaction with endothelial 
wall forms as well as a “nose” with chemokine recep-
tors localized on it. Then cell defines the direction 
of high chemokine concentration (Fig. 1) and migrates 
through tissues to this direction [30, 39].
Fig. 1. Stem cell migrates to the higher concentration of the che-
mokine
It is known that after CXCL12 gradient forming and 
ligand-receptor interactions start a special mechanism 
of feedback begins to work. Proteosomal degrada-
tion of CXCR4-UB stops, previously ubiquitinated 
CXCR-UB is deubiquitinated by USP14 and forward 
to plasma membrane. In addition to this CXCR4 gene 
is induced for expression [25]. The duration of these 
reactions from the moment of changes in signalling 
is about 60 min long.
Currently it is considered that the cell move-
ment is regulated in such a complex way as it is cur-
rently known for the process of gene transcription 
regulation [26]. We suppose that for cell movement 
to be regulated it is not the easiest task for the single 
cell. For the detecting of the right direction in the ligand 
concentration gradient formed the cell must evaluate 
simultaneously the state of its whole set of receptors, 
distinguish the difference in their state and appropri-
ately response to this difference.
The difference between the movement potential 
of whole cell body and lamellipodia must be consi-
dered as well.
Lipid rafts system with receptors works as a special 
receptor field, and the phenomenon of positive feed-
back [39] acts very similar to the mammalian uncon-
ditioned reflex. Observation of several authors [26, 39] 
allows us suggesting that the main role of chemokine 
signaling is obtaining and transducing the information 
to some hypothetical cell analyzer capable of coordi-
native reading of results arrived. This is required for 
their subsequent complex processing (pre-modeling) 
and preparing an answer in accordance to specific 
“instruction”-instincts algorithms [44]. Thus the cell 
behavior is probably determined not only by che-
mokine signaling influencing integrin activation and 
elimination as well as cell adhesion and proliferation 
status but also by the work of a putative analyser ca-
pable of considering both chemokine receptor status 
and different circumstances in cellular environment 
occurred [44].
There are evidences that in case of CML in the hybrid 
protein p210 Bcr/Abl hyperexpression certain thresh-
old is reached and then the transcriptional silencing 
of CXCR4 expression is induced, that leads to chemo-
taxis disruption [45]. The other possible explanation 
of CXCR4 downregulation is the lack of the normal 
c-Abl molecule. The lack of c-Abl apparently emerges 
when bcr/abl gene that expresses from bcr promotor 
shows to a hypothetical cell control system the excess 
of c-Abl available in the cell, and initiation of transcrip-
tion of the normal c-Abl from other, non-Philadelphia 
chromosome 9 does not occur (Fig. 2) [46].
Fig. 2. Stem cell tends to migrate in direction of higher concen-
tration of chemokine gradient. But, according to the hypothesis, 
no c-Abl is available at the tips of lamellipodia. This is because 
 c-Abl expression is not initiated by some cell control system 
as a result of the hybrid protein Bcr/Abl molecules overproduction
Presumably, as a result of the hybrid protein 
the lack of normal C-Abl (which is normally found 
at tips of lamellipodia where it phosphorylates 
WAVE3 and controls actin cytoskeleton dynamics) 
emerges within cell. If the hypothesis about the C-
Abl-free tips of lamellipodia in case of Philadelphia 
chromosome is correct, it is possible to suggest that 
cell might become “paralyzed”. After CXCR4 interacts 
with CXCL12 cell “sees” chemokines gradient, tries 
to mobilize itself for migration but remains still. How-
ever, this hypothesis needs experimental verification. 
Absence of normal C-Abl within cell can also explain 
violation of reparation [10, 15, 17], apoptosis and 
oxidative burst pheno menon [21–23]. Accumulating 
in large quantity at the places of proliferation, para-
lyzed young stem cells can massively rush into blood 
stream changing blood formula and cell composition 
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of bone marrow. The main signs of CML might occur 
at this stage: lowering of alkaline phosphatase levels, 
oxidative burst and others.
We suppose that blocking of hybrid Bcr/Abl gene 
with Imatinib (Fig. 3) leads to recovering of normal 
 C-Abl gene expression from chromosome 9, and 
after that cell “paralysis” disappears. Cell normalizes 
and likely migrates to its niche where its proliferation 
occurs. As soon as niches become occupied, cyto-
kine stimulation of early progenitor cells stops as well 
as chemokine stimulation of their migration. Of course, 
this effect might be visible in case of discontinuous 
use of Imatinib only.
Fig. 3. Molecules of hybrid Bcr/Abl protein are hidden from cell 
system control by Imatinib molecules, due to this Abl moiety 
of the hybrid protein is not visible for hypothetical cell control 
system, and expression of c-Abl from normal chromosome is initi-
ated. As a result, cell is normalized according to the hypothesis, 
cell migration and apoptosis are recovered, and oxidative burst 
disappears
MUTATION P190
In the light of our hypothesis disruption in reparation 
resulted from the lack of C-Abl in CML might enhance 
the changes of Imatinib delivery and changes in its in-
tracellular concentration. This might lead to quick Bcr/
Abl overproduction and to C-Abl deficit, and the sub-
sequent reparation disruption, mutation frequency 
elevations and to increased probability of malignant 
transformation among cells bearing bcr/abl rear-
rangement. As a result of this the malignant leukemic 
clones could emerge with high frequency, and blast 
crisis might develop rapidly. Malignant transformation 
is usually related to the activation of other signaling 
pathways than those that operate in non-transformed 
cells. It is known that in case of p210 CML signal-
ing goes through STAT1, STAT3 and STAT5 pathway 
in myeloid cells-progenitors, while in p190 Bcr/Abl 
CML signaling passes through IL-4, STAT6 pathway 
that are usually active not in myeloid, but in lymphoid 
cells [47]. This can also explain Bcr moiety shortening 
in p190 and p210 Bcr-Abl. The cause of this shortening 
is appa rently that in lymphoid cells the shorter variant 
of Bcr/Abl is translated as a result of an alternative 
splicing. In conditions of active mutagenesis and 
cell population selection “truncated” versions of bcr/
abl gene sufficient for transcription of Bcr moiety 
in p190 bcr-abl remain in population. This indicates 
that bcr moiety is apparently important for realization 
of malignant phenotype. Proliferation of malignant 
cells with bcr/abl p190 is likely possible to be in a niche 
of any stem cells of organism, that is why usage of Ima-
tinib may contri bute to generalization of proliferating 
sites of leukemic infiltration at blast crisis, restoring 
the ability of cells to migrate. To solve this problem 
AMD3100 (Plerixafor) which blocks CXCR4 receptors 
has been proposed. It has been shown that the use 
of AMD3100 consi derably lowers the resistance of leu-
kemic cells to the therapy [48]. Other researchers 
 using AMD3100 have achieved a favorable therapeutic 
effect when mobilizing CD34 stem cells for autotrans-
plantation of GSC to patients with multiple myeloma 
and non-Hodgkin lymphoma with just small side ef-
fects [49–52]. Using of AMD3100 leads to CXCR4 re-
ceptor inactivation that makes cell unable to sense 
chemokine gradient (Fig. 4). As a result, cell is inac-
tive, fixes badly to intracellular matrix and, probably, 
because of this can easily penetrate into blood stream.
Fig. 4. Usage of AMD3100 leads to CXCR4 receptor inactivation 
that makes cell unable to recognize gradient of the chemokine
As a result of series of experiments using 
AMD3100 and G-CSF for mobilization of CD34+ 
cell populations it has been shown that AMD3100-
mobilized CD34+ cells include more T- and B-cells 
progenitors, while cells mobilized with G-CSF have 
more granulocytes and mononuclear phagocytes 
progenitors [53]. These results lead to an interesting 
assumption. It is known that mature cells originate 
at the terminal differentiation of stem cells of ap-
propriate type. Maybe “myeloid” cells during CML 
differentiate at proliferation of earlier lymphoid line 
cells-progenitors, that has undergone chromosomal 
aberration with formation of Philadelphia chromo-
some. Thus, “myeloid” phenotype forms because 
the formation of a lymphoid phenotype is possible 
only when terminally differentiated lymphoid cells-
progenitors proliferate. In this case early lymphoid 
cells-progenitors [53] accumulating in a very large 
quantity have phenotype which is only similar to that 
of myeloid cells.
Thereby, the CML disease studying of currently 
identified molecular mechanisms of cell migration, 
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reparation and apoptosis has led to a significant 
progress in understanding CML nature. This allows 
us formulating a special hypothesis on the possible 
role of the hybrid Bcr-Abl molecule to deprive the cell 
of its ability to chemotaxis sensing the right direction 
of the ligand concentration gradient. We suppose that 
further researches in this field may lead to the improve-
ment in treatment methods of this disease.
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